Welcome to Amarantus BioSciences
Amarantus BioSciences, Inc. (“Amarantus”) is focused on the discovery and development of therapeutic proteins with the potential to address critically important biological pathways involved in the treatment human diseases.
The Company’s lead program MANF is aimed at developing products to address the underlying Programmed Cell Death (Apoptosis) associated a wide range of devastating human disorders. With a global trend towards an prolonged life expectancy due to novel therapies and emerging countries gaining access to critical medical care, the development of Apoptosis-related treatments represents a significant market opportunity that addresses a critical unmet medical need: safely and effectively improving currently-approved patients treatments.
Amarantus’ business strategy, utilizing Amarantus’ seasoned Management Team, world-class Scientific Advisory Board and Board of Directors, is to employ our PhenoGuard Drug Discovery Engine to discover medically-relevant secreted human proteins, scientifically establish their therapeutic potential, develop pre-clinical and clinical programs to further their development, and advance them through successive de-risking milestones to maximize their commercial potential while making them attractive partnering targets for product development focused biotechnology, pharmaceutical, medical device and diagnostic companies. (Read more)
Videos
Events
COMING SOON
Recent News
January 23rd 2012
Amarantus BioSciences Licenses Parkinson’s Disease Diagnostic Biomarker Test from Power3 Medical Products
Read more
January 20th 2012
Amarantus BioSciences Interview at the 2012 Biotech Showcase
Read more
January 12th 2012
Amarantus BioSciences to be Interviewed on The Big Biz Radio Show
Read more
January 11th 2012
Amarantus BioSciences Awarded US Patent Protecting Composition of Matter for MANF
Read more
January 9th 2012
NFL Veterans Corey Chavous and Jack Brewer Support Amarantus BioSciences’ Traumatic Brain Injury Research
Read more
January 3rd 2012
Amarantus BioSciences Updates Shareholders on Execution of Expanded Corporate Strategy
Read more
December 15th 2011
Amarantus BioSciences Appoints Mark J. Benedyk, PhD as Strategic Advisor
Read more
December 1st 2011
Amarantus BioSciences to Present at the National Investment Banking Association’s (NIBA) 120th Investment Conference
Read more
November 30th 2011
Amarantus BioSciences Receives Grant from Brewer Sports International for Traumatic Brain Injury
Read more
November 22nd 2011
Amarantus BioSciences and Banyan Biomarkers announce Traumatic Brain Injury Research Collaboration
Read more
November 15th 2011
Amarantus BioSciences’ Gerald and Dr. John Commissiong Selected as Black Money’s “50 Most Important African-Americans in Technology”
Read more
November 1st 2011
Amarantus BioSciences Expands Corporate Strategy Read more
October 28th 2011
Amarantus BioSciences Appoints Gerald Commissiong President & CEO Read more